A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07814859

Title field or adapter rule

{'original_value': 'A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.029887+00:00

Published At

2026-09-11T00:00:00+00:00

Record Updated At

2026-09-11

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-11", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07814859"

protocolSection.identificationModule.officialTitle

"A Prospective, Exploratory Study of Retlirafusp Alfa Combined With Famitinib and AG-Chemotherapy as First-Line Therapy for Unresectable Pancreatic Cancer"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['experimental group'], 'description': 'etlirafusp alfa (1800 mg, q3w, Cycle 1)，until the disease or toxicity becomes intolerable (whichever comes first)', 'name': 'Retlirafusp alfa Injection', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['experimental group'], 'description': 'Famitinib (15mg, once daily, every 3 weeks),until the disease or toxicity becomes intolerable (whichever comes first).', 'name': 'Famitinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['experimental group'], 'description': 'Albumin-bound paclitaxel (125mg/m² on days 1 and 8, every 3 weeks, for 6 cycles) combined with gemcitabine (1000mg/m² on days 1 and 8, every 3 weeks, for 6 cycles) until the disease progresses or toxicity becomes unbearable (whichever happens first).', 'name': 'AG', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Retlirafusp alfa Injection (protocolSection.armsInterventionsModule.interventions[].name)
• Famitinib (protocolSection.armsInterventionsModule.interventions[].name)
• AG (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.